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Drugadministration toavoidunpleasantdrugwithdrawal symptomshasbeenhypothesized tobea crucial factor that leads to compulsive
drug-taking behavior. However, the neural relationship between the aversive motivational state produced by drug withdrawal and the
development of the drug-dependent state still remains elusive. It has been observed that chronic exposure to drugs of abuse increases
brain-derivedneurotrophic factor (BDNF) levels inventral tegmental area (VTA)neurons. Inparticular,BDNFexpression isdramatically
increased during drugwithdrawal, whichwould suggest a direct connection between the aversive state of withdrawal andBDNF-induced
neuronal plasticity. Using lentivirus-mediated gene transfer to locally knock down the expression of the BDNF receptor tropomyosin-
receptor-kinase typeB in rats andmice,we observed that chronic opiate administration activates BDNF-relatedneuronal plasticity in the
VTA that is necessary forboth the establishmentof anopiate-dependent state andaversivewithdrawalmotivation.Our findingshighlight
the importance of a bivalent, plastic mechanism that drives the negative reinforcement underlying addiction.
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Introduction
The initial acute rewarding effect of a drug of abuse activates
adaptive neural mechanisms that counteract the departure from
a state of equilibrium, producing an aversive motivational state
when the drug has been cleared from the organism (Koob and Le
Moal, 2001; Vargas-Perez et al., 2007, 2009a). This withdrawal
from drugs of abuse produces a negative affective state including
symptoms of dysphoria, depression, irritability, and anxiety
(Koob and Le Moal, 2001), as well as increases in reward thresh-
olds and decreased tolerance to aversive stimuli (Zacharko and
Anisman, 1991; Koob and Le Moal, 2005). Thus, drug intake
stimulates a negative response that becomes sensitized during
repeated drug withdrawal and even persists into prolonged absti-
nence, contributing to drug-taking behavior (Koob and LeMoal,
2005). Avoiding the unpleasantness of the withdrawal state is
hypothesized to be an important factor that triggers compulsive
drug intake, potentially leading to drug addiction (Koob and
Bloom, 1988; Koob et al., 1989, 1992; Wise, 1996; Koob and Le
Moal, 1997, 2001; Vargas-Perez et al., 2007, 2009a).
The transition to a drug-dependent state is accompanied by a
series of plastic changes in brain reward circuits (Crabbe, 2002;Rob-
inson and Berridge, 2003; Kreek et al., 2005), which underlie con-
tinuing negative reinforcement driving and maintaining addiction
(Nader et al., 1997; Koob and Le Moal, 2005). For instance, the
transition fromanopiate-naive to anopiate-dependent state is asso-
ciatedwith a change, froman inhibitory to an excitatory response, of
the GABAA receptors located on GABA neurons in the ventral teg-
mental area (VTA; Laviolette et al., 2004). This change promotes a
shift from a dopamine-independentmotivational system, which in-
volves the brainstem tegmental pedunculopontine nucleus (TPP;
Bechara et al., 1995), to a dopamine-dependent opiate motiva-
tional system (Bechara et al., 1995). Recent evidence demon-
strated that an increase in brain-derived neurotrophic factor
(BDNF) levels is sufficient to switch the response of GABAA
receptors on VTA GABAergic neurons from inhibitory to excit-
atory, which in turn is sufficient to induce a transition to a drug-
dependent motivational state (Vargas-Perez et al., 2009b).
Chronic exposure to drugs of abuse increases BDNF levels in
VTA neurons (Bolan˜os and Nestler, 2004). In particular, BDNF
expression is significantly increased during drug withdrawal
(Vargas-Perez et al., 2009b), which suggests a direct connection
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between the aversive state of withdrawal and BDNF-induced
neuronal plasticity. Thus, we hypothesize that blocking BDNF sig-
naling in the VTA should block both the aversivemotivational state
produced by drug withdrawal and the development of the drug-
dependent state. To test this hypothesiswe used lentivirus-mediated
gene transfer to locallyknockdowntheexpressionofBDNFreceptor
tropomyosin-receptor-kinase type B (TrkB). We observed that
chronic opiate administration activates BDNF-related neuronal
plasticity in the VTA that is necessary for both the establishment of
an opiate-dependent state and aversive withdrawal motivation,
highlighting the importance of a bivalent, plastic mechanism that
drives the negative reinforcement underlying addiction.
Materials and Methods
Animals and surgery
All experimental protocols were approved by and conformed to the In-
stitutional and Governmental Animal Care Committee guidelines, in
accordance with principles of animal care (http://www.ccac.ca/).
For behavioral tests in which rats were used, subjects were Wistar
strain males (Charles River) weighing 350–500 g during experimental
training. Rats were housed individually in Plexiglas cages in a room
maintained at 22°C and lit from 7:00 A.M. to 7:00 P.M. Rats were given
food and water ad libitum throughout the experiment.
In the case of behavioral experiments using mice (VTA BDNF infu-
sions), subjects were wild-type male C57BL/6 weighing 25–30 g. Mice
were given food andwater ad libitum andmaintained at 22°C in Plexiglas
cages on a 12 h light/dark cycle.
Male GAD-GFP knock-in mice (50 d) were used for the iontopho-
retic recording of VTAGABAergic neurons.Mice were housed in groups
of four in Plexiglas mouse cages in a room at a temperature of 22°C with
lights on from 7:00 A.M. to 7:00 P.M.No animals were used inmore than
one experiment.
For VTA infusions, animals were anesthetized with inhaled isoflurane
(3%) and placed in a stereotaxic device. The procedure for rats involved
bilateral implantations of 22 gauge stainless steel guide cannulae (Plastics
One). The cannulae were implanted 2 mm dorsal to the VTA at a 10°
angle using the following coordinates relative to bregma: AP:5.6 mm,
ML:2.3 mm, and DV:7.8 mm from the dural surface (Paxinos and
Watson, 1986). For TPP temporary lesion 22 gauge stainless steel guide
cannulae (Plastics One) were bilaterally implanted 2 mm dorsal to the
TPP at a 10° angle using the following coordinates relative to bregma: AP:
7.6 mm, ML: 3.1 mm, and DV: 6.6 mm from the dural surface
(Paxinos and Watson, 1986). At least 2 weeks were allowed for postsur-
gical recovery preceding behavioral training.
Three stereotaxic surgical procedures were used for the mouse exper-
iments in Figure 5. The first procedure (implemented in Fig. 5a,b) in-
volved the use of 33 gauge needles to bilaterally infuse 0.025g or 0.25g
BDNF in the VTA coordinates previously used in our mouse work (AP:
3.0 mm, ML: 0.5 mm, DV: 4.2 from bregma). In the case of the
0.025g infusions, 0.05l was infused over the span of 1min after which
the needle was left stationary for another minute. In the case of the 0.25
g infusions, 0.5 l was infused over the span of 5 min after which the
needle was left stationary for another minute. The second procedure
(implemented in Fig. 5c) involved the infusion of 0.25 g BDNF in the
VTA coordinates used by Koo et al. (2012) (at a 7° angle, AP:3.2 mm,
ML: 1.0 mm, DV: 4.6 mm from bregma). Mice were left to recover
for 7 d before they were used in behavioral experiments.
Induction of opiate dependence
To induce opiate dependence in rats, animals received 0.5 mg/kg subcu-
taneous injections of heroin daily for 5 d (in line with the heroin pre-
exposure protocol; Laviolette et al., 2004). Animals were conditioned
21 h after their last heroin injection. During conditioning, this dose of
heroin was administered as a maintenance dose 3.25 h after the termina-
tion of training.
GAD-GFP knock-inmice weremade opiate dependent by the implan-
tation of subcutaneous osmoticmini pumps (Model 2001; AlzetOsmotic
Pumps) containing morphine solution (70 mg/ml; Dockstader et al.,
2001). Pumps were surgically implanted under isoflurane (2%) anesthe-
sia and aseptic conditions. The pumps delivered morphine (1.0l/h) for
5–7 d and then experiments were performed 12–16 h following surgical
removal of the pumps under isoflurane (2%) anesthesia. In naive animals
mini pumps that contained saline solution were implanted as a control.
The aversive effects of withdrawal induced by this regimen are similar
qualitatively to those observed after the heroin pre-exposure protocol
used in rats (Dockstader et al., 2001).
Drugs and microinjection procedure
The drugs used in these experimentsweremorphine sulfate (Almat Phar-
machem), diacetylmorphine hydrochloride (heroin; Almat Pharm-
achem), muscimol hydrobromide (Sigma), lithium chloride (LiCl;
Sigma), -flupenthixol (Sigma), or lidocaine hydrochloride (Sigma),
and were dissolved in physiological saline (pH adjusted to 7.4). Recom-
binant human BDNF (Sigma) was dissolved in PBS, pH 7.4).
In the rat experiments, bilateral VTA or TPP microinjections (0.5
l volume per infusion) were performed over 1 min. Injectors were
left in place for a further 1 min to ensure adequate diffusion from the
injector tip.
Viral vectors
To test for the necessity of BDNF signaling, we locally knocked down
TrkB gene expression in vivo, via siRNA-expressing lentiviral vectors
(LVs). Through bilateral stereotaxic surgery, we injected 0.5l of siRNA-
expressing LV (LV-siRNA1, LV-siRNA2, and LV-siRNA3, targeting
three separate regions of the mRNA; Bahi et al., 2008) against TrkB, or
the green fluorescent protein (GFP)-tagged lentiviral vector pTK433
(LV-GFP; Bahi et al., 2008) as a control, into the VTA of adult rats. It has
been observed that this coinfection mix of the three silencers (LV-
siRNAs) achieves93% silencing of TrkBmRNA (Bahi et al., 2008). The
three targets were designed according to the rat TrkB mRNA sequence.
The TrkB sequences were selected based on Hannon’s design criterion:
first target, bp 5–27; second target, bp 2438–2460; third target, bp 1500–
1522 (Bahi et al., 2008). LV-siRNAs were mixed with LV-GFP to localize
injection sites in experimental animals, and the LV-GFP was used alone
in the control animals. LVs were injected 1–2 weeks before electrophys-
iological experiments or behavioral testing.
Histology
At the end of experiments, animalswere deeply anesthetizedwith sodium
pentobarbital (35 mg/kg, i.p.) and were perfused intracardially with 200
ml of PBS followed by 400 ml of 4% paraformaldehyde. Brains were
removed rapidly and stored for 12 h in a 35% sucrose/PBS solution.
Brains then were flash frozen at80°C, sliced in a freezing microtome at
20°C into 30-m-thick sections, and mounted on gelatin-coated
slides. Brain sections were stained with cresyl violet and subsequently
examined by light microscopy.
Immunostaining for TrkB expression in VTA GABAergic neurons
Rats were anesthetized with sodium pentobarbital (35 mg/kg, i.p.) and
perfused intracardially with 200 ml of PBS followed by 400 ml of 4%
paraformaldehyde. Brains were rapidly removed and stored for 12 h in a
35% sucrose/PBS solution. Brains were then flash frozen at80°C, sliced
in a freezing microtome at 20°C into 20-m-thick sections, and
mounted on gelatin-coated slides. Brain sections were blocked with 10%
normal goat serum in PBS for 1 h at room temperature. TrkB (mouse
monoclonal antibody, 1:50; BD Transduction Laboratories) and MAP-2
(chicken polyclonal, 1:10,000; Abcam) antibodies were incubated at 4°C
overnight. Slides were then washed three times with PBS and incubated
with Alexa-conjugated secondary antibodies at a concentration of 1:400
for 1 h at room temperature. All antibody dilutions were made in 10%
NGS containing PBS. Slides were washed, dried, and mounted and im-
aging was performed using an Olympus FV1000 confocal microscope.
To accurately assess the percentage of GFP cells that coexpress the
TrkB receptor after LV infection of siRNAs or GFP, coronal sections
(approximately 5.6 mm from bregma) containing the VTA (Paxinos
and Watson, 1986) from the brain of three animals per condition were
immunohistochemically labeled for GFP and TrkB. To measure cell size,
ImageJ software (NIH) was used to measure the area of cell bodies of 46
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neurons in each condition. A comparison of GFP TrkB-positive VTA
neurons between LV-GFP and LV-siRNAs-infected animals was made
using a Student’s t test, with a minimum of 100 GFP-positive neurons
counted per animal.
Iontophoretic recording of VTA GABAergic neurons
Preparation of tissue slices for electrophysiological recordings. For brain
extraction, mice were anesthetized with isoflurane (5%) and intraperito-
neal injection of ketamine (60 mg/kg) and decapitated. The brain was
quickly removed from the craniumand glued onto a cutting stage. Slicing
was performed using a sapphire blade (ElectronMicroscopy Sciences) on
a vibratome tissue slicer in an ice-cold cutting solution containing the
following (in mM): 220 sucrose, 3 KCl, 1.25 NaH2PO4, 25 NaHCO3, 12
MgSO4, 10 glucose, 0.2 CaCl2, and 0.4 ketamine perfused with 95% O2
and 5% CO2. Horizontal slices (210 m thick) containing the VTA were
cut and transferred into an incubation chamber containing artificial CSF
(ACSF) containing the following (in mM): 124 NaCl, 2 KCl, 1.25
NaH2PO4, 26 NaHCO3, 12 glucose, and 1.2 MgSO4 2 CaCl2 perfused
with 95% O2 and 5% CO2 at 32°C for at least 30 min. Following incuba-
tion, slices were transferred to a recording chamberwith continuous flow
of ACSF maintained at 36°C throughout the experiment.
Characterization of VTA GABA neurons in vitro. In GAD-GFP
knock-in mice (Tamamaki et al., 2003), GABA neurons were studied in
horizontal brain slices with the aid of fluorescencemicroscopy. The VTA
was visualized by first locating the substantia nigra reticulata (SNr) in the
horizontal slice preparation under low power (4) with fluorescence
illumination. The SNr has a characteristic glow under low magnification
with GFP fluorescence optics, likely due to dense GABA terminal inner-
vation. Substantia nigra compacta was then identified medial to SNr.
GABAneurons in theVTAwere studied by visualizingGADneurons in
an area medial to the glowing SNr, posterior to the fasciculus retroflexus
and mammillothalamic tract, anterior to the decussation of the superior
cerebellar peduncle, and dorsal to the interpeduncular nucleus (Stef-
fensen et al., 2011; Ting-A-Kee et al., 2013). Neurons in the VTA of
GAD-GFPmice that did not fluoresce but exhibited a noncation-specific
inward rectifying current (Ih) in combination with relatively low input
resistance and regular, slow spike activity were assumed to be DA neu-
rons (Steffensen et al., 2011; Ting-A-Kee et al., 2013).
Cell-attached, voltage-clamp recording of spike activity in brain slices.
Electrodes were pulled from borosilicate glass capillaries and then filled
with 150 mM NaCl (3–5 M). Positive pressure was applied to the elec-
trode when approaching the neuron. By applying suction to the elec-
trode, a seal (10 M–1 G) was created between the cell membrane and
the recording pipette. Spontaneous GABA firing activity was recorded in
voltage-clamp mode with a Molecular Devices Multiclamp 700B ampli-
fier and sampled at 10 kHz using an Axon 1440A digitizer, and collected
and analyzed using pClamp10 software. Neurons were voltage clamped
at 0 mV throughout the experiment. First, a stable baseline recording of
firing activity was obtained for 5–10 min. Two methods were used to
assess the effects of muscimol on VTA GABA neuron firing rate. In some
slices, only one dose of muscimol (Sigma-Aldrich; 0.01–1 M) was stud-
ied on one cell in each slice. In other slices, a wash was performed be-
tween superfusions of different concentrations of muscimol on the same
cell (5–10 min at each dose with 10 min between doses). Regardless, no
more than one cell was studied per slice and no more than three slices
were studied per animal. One-way repeated-measures ANOVA and
Tukey’s post hoc test were performed to compare LV-GFP-naive, LV-
siRNAs-naive, LV-GFP-dependent, and LV-siRNAs-dependent groups.
Rat place preference test
The place-conditioning apparatus and conditioning procedures were
identical to previous studies (Vargas-Perez et al., 2009a). Conditioning
took place in one of two distinct environments (41 41 38 cm), which
differed in color, texture, and smell. One environment was white, with a
wire mesh floor. The other environment was black, with a smooth Plexi-
glas floor that was wiped down with a 12% acetic acid solution before
each conditioning session. These conditioning environments are moti-
vationally balanced such that animals show no initial preference for ei-
ther environment before conditioning (Laviolette et al., 2004). During
testing, each rat was placed at the neutral gray zone (41  10 cm) that
separated the two compartments and was allowed to explore both envi-
ronments freely for a period of 10 min. Testing was performed drug free,
at least 2 d after the final conditioning session.
For experiments that examined the direct effect of a drug, rats were
conditioned with a fully counterbalanced place-conditioning procedure
described previously as procedure B (Vargas-Perez et al., 2009a). In this
procedure, rats were exposed to both conditioning environments in a
fully counterbalanced order. All experimental groups received four drug-
environment and four saline-environment conditioning sessions for 40
min over 8 consecutive days. Two days later, rats were tested drug free
and the time spent in each environment was recorded over a 10 min test
period.
Under this place-conditioning procedure we assessed the rewarding
effects of morphine (10 mg/kg), the aversive effects of LiCl (5 mg/kg),
and the aversive effects of naloxone-precipitatedwithdrawal (5mg/kg) in
LV-GFP against LV-siRNAs-infected, opiate-dependent rats. The re-
warding effects of morphine and naloxone were tested, in naive and
dependent animals. Morphine was administrated after the blockade of
the dopaminergic system with the neuroleptic -flupenthixol (0.8 mg/
kg, i.p,)–administered 2.5 h before conditioning. Additionally, in a new
group of animals, we test the rewarding effects of morphine after the
temporary inactivation of the TPP. Bilateral TPP temporary inactivation
was performed 2 min before conditioning by microinfusing 5 l of lido-
caine (4%; Vargas-Perez et al., 2009a). Sham temporary-inactivation an-
imals received bilateral injections of PBS.
To assess the effect of spontaneous withdrawal from morphine in
dependent rats, we used a modified place-conditioning procedure for
which conditioning took place in only one compartment (Procedure W
or withdrawal-paired) of the place-conditioning apparatus (Vargas-
Perez et al., 2009a). Briefly, each dependent rat, by means of the heroin
pre-exposure protocol, intraperitoneally received 3 mg/kg of morphine.
Approximately 16 h after the morphine injection (Bechara et al., 1995;
Vargas-Perez et al., 2007, 2009a), each rat was injected with saline vehicle
and then exposed immediately to a distinct conditioning environment
for 40 min. This procedure was repeated four times over 8 d. As a result,
one of the two compartments was paired with the absence of morphine
and the other was an unfamiliar, neutral environment. The time spent in
each environment was recorded over a 10min test period. Times spent in
each environment were scored separately for each animal.
Mouse place preference test
The place conditioning apparatus (Med-Associates SOF-700RA-25) used
consisted of a black compartment with metal rod floor, a white compart-
ment with a wire mesh floor, and a gray compartment in the middle that
contained a partition on both sides. Two unbiased conditioned place pref-
erence paradigms were used. The first was composed of eight, 15 min long
conditioning sessions conducted over the span of 8 d (i.e., one session per
day). The compartments towhich themorphine (5mg/kg) and saline injec-
tions were paired were counterbalanced. On the ninth day, the partitions
between the compartments were removed andmice were placed in the gray
zone and allowed to roam freely for 10min. The second conditioning para-
digm(Kooet al., 2012)was composedof six or eight, 45min long condition-
ing sessions conducted over the span of 3 d or 4 d, respectively (i.e., two
sessionsper day). Saline conditioningwas alwaysperformed in themorning,
while morphine (15 mg/kg) conditioning was performed in the afternoon.
On the day following the last day of conditioning, animalswere placed in the
gray zone and allowed to roam freely between the compartments for 20min.
For place-conditioning experiments, statistical analysis was performed
using a two-way or three-way ANOVA. Post hoc Student–Newman–Keuls
tests or Student’s t tests were performed where appropriate.
Opiate-withdrawal somatic signs, ultrasonic distress vocalizations,
and locomotor sensitization
Rats were observed for somatic signs of opiate withdrawal 16 h after
heroin injections compared with saline-treated rats. Typical abstinence
signs in rats included body and head shakes, cheek tremors, eye blinks,
ptosis, foot and genital licks, scratches, writhes, and gasps (Grieder et al.,
2010). Each rat’s percentage abstinence scores were its number of
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observed abstinence signs divided by the average of abstinence signs
observed in saline-treated rats andmultiplied by 100. One-way repeated-
measures ANOVA and post hoc Fisher’s least-significant difference tests
were performed to compare the differences in the number of percentage
abstinence scores among groups.
Ultrasonic distress vocalizations in the 20–28 kHz range were recorded
for10min following the administrationof theopioid antagonist naloxone in
naive and chronic opiate-treatedLV-siRNAs rats and chronic opiate-treated
LV-GFP rats. Animals were brought to an empty room and placed inside a
gray chamber (41 41 38 cm), where ultrasonic vocalizations (s) were
recorded and transformed into an audible signal with the aid of Mini Bat
Detectors (Ultra SoundAdvice). The signal was sent to a computer, where it
was digitized for analysis. A Student’s t test was performed to compare the
difference in the number of ultrasonic distress vocalizations emitted by the
two groups.
The test of locomotor activation produced by repeated opiate admin-
istration was performed in a gray chamber (41  41  38 cm) during
daylight. A camera positioned above the chamber recorded distance trav-
eled (meters) using EthoVision XT (version 5) software (Noldus Infor-
mation Technology). Locomotor activity was monitored at least 2 weeks
after surgery. The first day, rats were placed drug free in the activity
chamber for 10 min after the subcutaneous injection of saline solution.
On subsequent days, rats were placed in the activity chamber for 10 min
immediately after the subcutaneous injection of 0.5mg/kg of heroin. Rat
locomotion was recorded on drug-free day (day 0) and on days 1 and 4
after heroin administrations. One-way repeated-measures ANOVA and
post hoc Student–Newman–Keuls tests were performed to compare the
effects of heroin on locomotion in LV-GFP- against LV-siRNAs-infected
rats. The experimental time line of LV infections and intra-VTA BDNF
infusion experiments are described in Table 1 and Table 2, respectively.
Results
We found that rats coinjected with LV-siRNAs against TrkB
showed a selective loss of TrkB expression in the VTA as deter-
mined by immunohistochemistry (Fig. 1). In slices taken from
the VTA (Fig. 1c), confocal microscopy revealed a80% reduc-
tion (t(5)  2.77, p  0.003) in the detection of TrkB receptor-
expressing cells after injection of GFP-labeled LV-siRNAs
compared with LV-GFP control (Fig. 1a,d). Furthermore, as de-
scribed previously (Bolan˜os and Nestler, 2004), an overall trend,
but not significant, decrease in the soma size (micrometers) of
VTA LV-siRNAs-positive neurons with respect to the VTA LV-
GFP control was detected (mean  SEM: LV-siRNAs, 55.94 
3.74; LV-GFP, 50.16 7.39; t(91) 1.08, p 0.57; Fig. 1b).
The TrkB receptor mediates the adaptive response of VTA
GABA neurons after chronic morphine administration
The shift from inhibitory to excitatory GABAA receptor signaling
induced by chronic opiate administration and withdrawal was
blocked in LV-siRNAs-treated animals, but not in LV-GFP con-
trol animals. The average firing rate of VTA GABA neurons re-
corded in LV-GFP Naive mice in the horizontal slice preparation
ex vivowas 12.9 1.9Hz (n 14), in LV-siRNAsNaivemice was
9.0 2.5 Hz (n 6), in LV-GFP Dependent mice was 22.3 4.9
Hz (n 9), and in LV-siRNAsDependentmicewas 17.2 3.5Hz
(n  9). Although the mean baseline firing rate of LV-GFP De-
pendent mice in the slice preparation was greater than LV-GFP
Naive mice, as we have previously demonstrated in morphine-
dependent mice in vivo (Vargas-Perez, 2009b), it was not signif-
icantly greater (p  0.05), perhaps because of the pronounced
variability in baseline rate across cells in the slice preparation.
However, muscimol (0.01–1.0 mM) briskly and markedly inhibited
VTA GABA neuron firing rate in LV-GFP Naive mice (Fig. 2a)
and LV-siRNAsNaivemice (Fig. 2b), slightly enhanced firing rate
in LV-GFP Dependent mice (Fig. 2c), and inhibited VTA GABA
neuron firing rate in LV-siRNAs Dependent mice (Fig. 2d), re-
gardless of baseline firing rate. In these examples, cells with sim-
ilar firing rates (	10 Hz) were chosen for comparison. Figure 2e
summarizes the effects of muscimol (0.01–1.0 mM) across all
groups of mice. ANOVA revealed no overall difference between
groups at 0.01mMmuscimol (p 0.055, F(1,26) 2.93), but there
were significant overall differences between groups at 0.1 mM
muscimol (F(1,30)  13.62, p  0.0001) and 1.0 mM muscimol
(F(1,25) 6.76, p 0.002). Tukey’s post hoc test revealed a signif-
icant difference between LV-GFPNaive versus LV-GFPDependent
mice at the 0.1mM (p 0.0001) and 1.0mM (p 0.003)muscimol
levels and LV-GFP Dependent versus LV-siRNAs Dependent mice
at the 0.1mM(p0.0001) and1.0mM(p0.002)muscimol levels.
There was no significant difference between LV-GFP Naive versus
LV-siRNAs Naive mice or between LV-siRNAs Naive versus LV-
siRNAs Dependent mice at any dose level (p 0.05).
BDNF signaling in the VTA is necessary for the switch to a
drug-dependent state motivational system
Blocking TrkB function in the VTA was sufficient to reduce the
increased locomotor activation produced by repeated opiate ad-
ministration observed in LV-GFP (p  0.04, n  7); however
there was still an effect of heroin on locomotion activation in the
LV-siRNAs (n  7) group compared with LV-siRNAs (n  8)
naive animals (p 0.035). No significant differences were found
between LV-siRNAs and LV-GFP (n  8)-infected opiate naive
groups (effect of heroin treatment: F(3,89)  3.7, p  0.024; LV
treatment: F(1,89) 3.4, p 0.039; effects of days: F(2,89) 3.89,
p  0.024; Fig. 3a). Additionally, blocking TrkB function in the
VTA was sufficient to keep the animals in a motivationally opiate
naive-like state, even after chronic opiate exposure (Fig. 3b,c).
Using conditioned place preference procedures in rats infected
with LV-siRNAs or LV-GFP in the VTA, we observed that BDNF
in the VTA is necessary for the switching mechanism from a
nondopamine, opiate-naive motivational reward system to a do-
paminergic, opiate-dependent motivational system. In contrast
to control LV-GFP (n  8 per group)-infected animals, where
antagonism of the dopaminergic system with the neuroleptic
-flupenthixol (0.8 mg/kg) blocked the rewarding effects of sys-
temic morphine in drug-dependent rats (p  0.12), similarly
treated rats infected with LV-siRNAs (n 8 per group) showed
conditioned place preferences that were not blocked by
-flupenthixol (p 0.001; F(1,63) 4.0, p 0.001, interaction of
morphine, neuroleptic, and LV treatment; Fig. 3b). However, as
is the case in opiate-naive animals (Vargas-Perez et al., 2009a),
the rewarding properties of acute morphine administration were
blocked by TPP inactivation in LV-siRNAs (n 8) rats chronically
opiate treated and in withdrawal (p 0.73). TPP inactivation dur-
ing conditioning did not affect the morphine place preferences in
LV-GFP (n 8)-infected animals with similar chronic opiate treat-
ments (p0.0001).PBSShamTPP inactivations, in chronicopiate-
treated and withdrawn animals, did not affect the expression of
morphine place preferences in LV-GFP (n  8) and LV-siRNAs
(n8;p0.0001;F(1,63)8.0,p0.006, interactionofmorphine,
TPP inactivation and LV treatment; Fig. 3c). It is possible that intra-
VTA LV-siRNAs infections modify the ability of opiates to produce
conditioned place preferences. However, neither LV-siRNAs nor
LV-GFP infections had any effect on the sizes of the conditioned
placepreferencesproducedbymorphine innaiveanimalspretreated
with-flupenthixol (p 0.001) or in the control group (p 0.001;
F(1,57)  1.96, p  0.168, interaction of drug and LV treatment;
LV-siRNAs neuroleptic, n 7; LV-siRNAs control, n 8; LV-GFP
neuroleptic, n 7; LV-GFP neuroleptic n 7; Fig. 3d).
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BDNF signaling in the VTA is necessary for the aversive
motivation of opiate withdrawal in dependent animals, but
not for the expression of somatic withdrawal signs
Chronic opiate exposure produced a daily increase in the expres-
sion of spontaneous somatic withdrawal signs in both LV-
siRNAs (n  8) and LV-GFP (n  8) after 16 h of heroin
administration (F(2,23)  5.6, p  0.0001), compared with
nonopiate-treated control rats (n  8; p  0.00001; Fig. 4a).
However, the aversive state associated with opiate withdrawal
was blocked in LV-siRNAs (n 8) rats compared with the con-
trol LV-GFP (n 8) animals. This aversive state was inferred by
monitoring low-frequency s, which are associated with negative
events (Hamdani and White, 2011). A decreased expression of
vocalizations in the 22 kHz range was observed following the
Table 1. Description of experimental time line for LV infections experiments
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administration of the opioid antagonist naloxone in LV-siRNAs
rats as compared with LV-GFP in naive (p  0.01) and chronic
opiate-treated (p 0.001) rats (F(1,27) 0.48, p 0.001, effect of
LV treatment; Fig. 4b).
We observed that knocking down TrkB expression with LV-
siRNAs (n  8) reduced the expression of the aversive motiva-
tional effects of withdrawal in chronic opiate-treated animals, in
contrast to LV-GFP (n  8) animals, which show conditioned
place aversions to an environment paired with 16 h of opiate
withdrawal (F(1,31) 5.20, p 0.03, interaction of LV treatment
and withdrawal; Fig. 4c). In addition, the aversive motivational
effects of the opioid antagonist naloxone were blocked in both
naive (n  8) and chronic (n  8) opiate-treated rats infected
with LV-siRNAs in the VTA, but not in LV-GFP naive (p 
0.001 n 8) and chronic opiate-treated rats (p 0.001, n 8;
F(1,63)  16.4, p  0.001, interaction of LV treatment and
naloxone; Fig. 4d).
LV-siRNAs infection in the VTA did not block the aversive
effects of all drug stimuli, as LV-siRNAs (n  8) and LV-GFP
(n  8)-treated rats expressed similar conditioned place aver-
Table 2. Description of experimental time line for intra-VTA BDNF infusions experiments
 
 
Effects of 0.25ug vs. 
0.025ug BDNF on 
5mg/kg morphine place 
preferences 
(Figure 5A) 
Effects of 0.25ug BDNF 
on 15mg/kg morphine 
place preferences 
(Figure 5B and C) 
recovery 
1 week 3 or 4 days 
place preference 
Following day 
Test VTA BDNF infusion
+
Alpha-flupenthixol
(0.8mg/kg) or 
saline recovery 
1 week 
place preference 
8 days  
Test 
2 days 
VTA BDNF infusion +++++ + ++
+
Alpha-flupenthixol 
(0.8mg/kg) or 
saline Effects of 0.25ug 
subarachnoid BDNF on 
15mg/kg morphine 
place preferences 
(Figure 5D) 
recovery
1 week 3 or 4 days 
place preference 
Following day 
Test BDNF infusion  ++ ++
 erudecorP tnemirepxE
Figure 1. Photomicrographs of rat coronal sections identifying lentiviral infections in the VTA. a, Double-labeled cell with GFP (green) and TrkB (red). Nuclei are in blue, in GFP lentiviral vector
pTK433 (LV-GFP)-infected animals (left) and siRNAs expressing lentiviral-infected (LV-siRNAs) and LV-GFP animals (right). Yellowdenotes the overlapping of LV-GFP and TrkB labeling,which is very
prominent is control animals (LV-GFP) and almost absent in LV-siRNAs-infected animals (arrow). b, Identification of LV-GFP (left) and LV-siRNAs (right) infections in VTA neurons labeled with the
neuronal marker MAP2 (cyan). An overall decrease in sizes of VTA LV-siRNAs-positive neurons with respect to the VTA LV-GFP control can be observed (compare arrowed neurons on the left and
right). c, A schematic of the anatomical region fromwhich the section displayed ina andbwas taken.d, Inhibition of TrkB expression in theVTAmediated by LV-siRNAs (n6) as opposed to control
LV-GFP (n 6; *p
 0.05). Data are numbers of TrkB-positive cells, expressed as a percentage of the LV-GFP control SEM.
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sions produced by intraperitoneal LiCl administration (F(1,31)
1.22, p  0.27, interaction of LiCl and LV treatment; Fig. 4e).
These results demonstrate the importance of BDNF-related neu-
ronal plasticity in the VTA for mediating the negative motiva-
tional state associated with opiate withdrawal.
BDNF-TrkB signaling in the VTA is sufficient for inducing
opiate dependence in mice
Recent work has suggested that VTA BDNFmay blockmorphine
place preferences (Koo et al., 2012), in contrast to our data show-
ing that VTA BDNF preserves morphine place preferences but
switches the brain substrates underlying themorphine place pref-
erences (Vargas-Perez et al., 2009b). Given that this more recent
work used a mouse model, a different conditioned place prefer-
ence paradigm, larger BDNF and morphine doses, and different
VTA coordinates from our mouse and rat work, we performed a
series of experiments to investigate whether BDNF-TrkB signal-
ing played a dual role with regards to opiate reward. First, we
tested the possibility that high doses of BDNF (0.25 g/mouse;
Koo et al., 2012) in mice give rise to different effects from doses
equivalent to what we had previously used in our rat work (0.025
g/mouse; Vargas-Perez et al., 2009a).
We found that, similar to controls (n 5),
mice receiving the smaller dose of BDNF
(n 13) and those treated with the higher
dose showed similarmorphine place pref-
erences (n 9, F(2,24) 0.507, p 0.608
interaction of morphine and treatment)
and those preferences were blocked by
-flupenthixol in both BDNF groups
(n 5 for the 0.025 g BDNF group and
n 4; for the 0.25g BDNF group; F(1,15)
 5.317, p  0.03, interaction of
-flupenthixol and BDNF treatment; Fig.
5a). Second, we investigated whether the
use of high doses ofmorphine in conjunc-
tion with a longer conditioning time (Koo
et al., 2012) results in a BDNF-dependent
suppression of morphine place prefer-
ences perhaps due to the prolonged dura-
tion revealing some aversive properties
of the morphine. Once again, BDNF had
no suppressive effects on morphine
place preferences, such that controls
showed an equivalent preference as
compared with BDNF-treated animals
(controls: n  7; BDNF group: n  9;
F(1,14) 0.232, p 0.637, interaction of
morphine and treatment; Fig. 5b).
Third, we used the same VTA coordi-
nates used by Koo et al. (2012) and
found that, even after accounting for all
the major differences in methodology,
we could not replicate their effect; con-
trols and BDNF-treated animals spent
similar amounts of time in the
morphine-paired compartment (n  7
and n  9, respectively; F(1,14)  1.037,
p  0.325, interaction of morphine and
treatment; Fig. 5c). Therefore, VTA
BDNF did not attenuate morphine place
preferences; instead, it changed the neu-
ral substrates mediating the preferences.
Discussion
Selectively knocking down TrkB receptor expression in the VTA
blocks the shift from inhibitory to excitatory GABAA receptor
signaling induced by chronic opiate administration and with-
drawal, keeping the animals in a motivational opiate naive-like
state. We observed that muscimol robustly inhibited the firing
rate of VTA GABA neurons at low concentrations (1.0 mM) in
all LV-GFP naive mice, LV-siRNAs naive mice, and LV-siRNAs-
dependent mice, but not in LV-GFP-dependent mice, indicating
that the adaptive response of VTA GABA neurons to chronic
morphine treatment is due to activation of TrkB receptors. Con-
sequently, BDNF signaling is necessary for the shift in GABAA
receptors on GABAergic VTA neurons, from inhibitory to excit-
atory. This neuronal change would cause the sensitization of in-
hibitory GABAergic signaling over dopaminergic neurons in the
VTA, altering the activity of the mesolimbic dopaminergic sys-
tem (White, 1996). Converging lines of evidence suggest that a
change in the function of themesolimbic dopaminergic system is
implicated in the aversive motivational response to drug with-
drawal (Grieder et al., 2010; George et al., 2012). Accordingly, we
Figure 2. Blockade of TrkB receptors prevents the switch in GABAA receptor function in VTA GABA neurons. VTA GABA neurons
in GAD GFP mice were visualized with fluorescent optics and recorded in cell-attached mode under voltage-clamp conditions.
Insets i and ii in a– d are representative 5 s traces of VTA GABA neuron spiking before and during 0.1 mM muscimol application
taken at the places indicated on each respective rate meter. Representative cells from each group of mice were chosen based on
similarity in baseline firing rate (	10Hz). Ratemeters fromeachgroupare shown in response to 0.1mMmuscimol. Althoughmost
cells recovered fully from muscimol, wash data are not shown, as the kinetics of recovery from muscimol varied considerably. All
axes ina– d are normalized to facilitate comparisons between groups.a, This ratemeter shows a representative VTAGABAneuron
recorded in an LV-GFP Naive mouse. Superfusion of muscimol markedly inhibited the firing rate of this VTA GABA neuron. b,
Similarly, muscimol markedly inhibited the firing rate of a representative VTA GABA neuron in an LV-siRNAs Naive mouse. c,
However, muscimol slightly enhanced the firing rate of a representative VTA GABA neuron in an LV-GFP Dependent mouse. d,
Similar to LV-GFPNaiveandLV-siRNAsmice,muscimol inhibited the firing rateof a representativeVTAGABAneuron inanLV-siRNA
Dependentmouse.e, Comparisonofmuscimol (0.01–1.0mM)effects on the firing rate of all VTAGABAneurons recorded in the four
groups ofmice following 16 hmorphinewithdrawal.Muscimol significantly reduced VTAGABAneuron firing rate in LV-GFPNaive,
LV-siRNAs Naive, and LV-siRNAs Dependent mice, but not in LV-GFP Dependent mice (*p
 0.05).
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observed that blocking BDNF signaling prevented the expression
of conditioned (i.e., conditioned place aversion) and uncondi-
tioned (i.e., vocalizations) aversive motivational states related to
opiate withdrawal. However, thesemanipulations did not cause a
general loss of the ability to detect aversive events or the expres-
sion of unconditioned withdrawal, as LV-siRNAs-infected ani-
mals were able to learn conditioned place aversion caused by LiCl
and the expression of withdrawal somatic sign were not affected.
Furthermore, the intra-VTA infection with LV-siRNAs by itself
did not cause any significant effect on behavior as shown by the
size of the conditioned place preference produced by morphine
in naive animals.
In naive rats, activation of GABAA receptors located on VTA
GABAergic neurons results in an inhibitory conductance medi-
ated by Cl influx. In naive rats, morphine activation of mu-
opiate receptors on presynaptic GABAergic terminals in the
VTA–which form inhibitory synapses on VTA GABAergic neu-
rons–inhibit them by decreasing the level of GABA release onto
their GABAA receptors. This disinhibition of GABAergic neuron
activity inhibits the mesolimbic dopaminergic pathway and pro-
duces reward through a nondopaminergic, TPP-mediated path-
way (Vargas-Perez et al., 2009b).
When rats are opiate dependent and in withdrawal, GABAA
receptors on VTA GABA neurons switch their signaling proper-
ties from inhibitory to excitatory (Vargas-Perez et al., 2009b). It
has been observed that a single bilateral intra-VTA BDNF infu-
sion (0.25 g/0.5 l each, but not at doses 50 larger and 10
the volume; Koo et al., 2012) promotes this switching mecha-
nism. BDNF may reduce the levels of the potassium chloride
cotransporterKCC2, thereby increasing the intracellular chloride
concentration. GABAA receptor activation then would result in
anions flooding out of the neuron (Ting-A-Kee et al., 2013). Al-
ternatively, BDNF infusions may elevate intracellular carbonic
anhydrase enzyme levels, thereby encouraging HCO3 efflux in
response toGABAA receptor activation (Ting-A-Kee et al., 2013).
These possible changeswouldmake the neuron’smembrane poten-
tial more positive, or depolarized, relative to the resting membrane
potentialunderlyingboth thedrug-dependent state and theaversion
towithdrawal. In opiate-dependent rats, opioid inhibition ofGABA
release from afferents to VTA GABAergic neurons results in less
activation of this now excitatory GABAergic input. This limits the
inhibitoryGABAergic input to theVTAdopamineneurons, thereby
increasing the activity of the mesolimbic dopaminergic system.
Thus, blockade of BDNF signaling, via the knockdown of BDNF
TrkB receptors (using LV-siRNAs), does not block morphine-
conditioned place preference (Koo et al., 2012), but prevents the
switch from a TPP-dependent reward system to a dopamine-
dependentmotivational systemandalsoprevents the expressionof a
withdrawal aversive motivational state.
In addition to this specific effect of BDNF on VTA GABA
neuron TrkB receptors, other BDNF-related plastic changes also
might occur. For example, it has been observed that BDNF in
high doses can also bind p75 receptors, inducing cell death. Thus,
higher doses and larger volumes of external BDNF (that cause
Figure3. Opiatemotivational effects in opiate-dependent animals after blocking the function of BDNF in theVTA.a, Depletion of TrkB expression in theVTA reduces but does not block locomotor
sensitization inducedby chronic heroin administration. Animals infectedwith LV-GFP (n7) showan increase in locomotionafter repeatedheroin administrations, comparedwith animals infected
with LV-siRNAs (n 7; *p
 0.05). However, there is an effect of heroin in locomotion activation in LV-siRNAs groups comparedwith naive LV-siRNAs (n 8) and LV-GFP (n 8) animals (*p

0.05).b, Blockadeof thedopaminergic systemwithneuroleptics (-flupenthixol, 0.8mg/kg) fails to block the rewarding effects ofmorphine (10mg/kg) in dependent rats after intra-VTA LV-siRNAs
infection (n 8 per group; *p
 0.05), opposite to LV-GFP-infected animals (n 8 per group), where the pretreatment with neuroleptics blocks any morphine place preference. c, Reversible
lidocaine (4%) TPP lesions (n 8), but no Sham lesions (n 8), block the rewarding properties ofmorphine administration in drug-dependent animals after intra-VTA LV-siRNAs infection, but the
same inactivation of the TPP (n8), as occurs in Sham lesions (n8), does not affectmorphineplace preference in LV-GFP animals (*p
0.05).d, LV-siRNAs (n8), comparedwith LV-GFP (n
7), infections do not affect the size of the conditioned place preference produced by acute morphine administration in drug-nondependent rats (*p
 0.05). Data represent means SEM the
absolute times spent during testing in the previously saline and previously morphine-paired compartments.
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blockade of the rewarding effects of morphine administration;
Koo et al., 2012) could be due to nonspecific neuroplastic
changes on VTA neurons that are unrelated to TrkB signaling.
We hypothesized that the nonspecific effects of external infusion
of BDNF, at high doses, on the motivational properties of mor-
phine would be independent of TrkB signaling, but found that
regardless of the dose, BDNF always had the same effect; it in-
duced an opiate-dependent state wherein dopamine signaling
was necessary for morphine-conditioned place preferences, and
did not suppress morphine preferences as previously indicated
(Koo et al., 2012). This effect was very robust considering that the
dose of morphine, length of conditioning, and specific VTA co-
ordinates did not reveal a different role for BDNF as suggested by
Koo et al. (2012). It is important to note that, unlike Koo et al.
(2012), our work does not directly address the role of BDNF-
TrkB signaling in the dopamine neurons of the VTA. However, if
it is in fact the case that BDNF-mediated neuroplastic changes at
the level of VTA dopamine neurons negatively modulate mor-
phine reward, it may be the case that TrkB signaling following
exogenous application of BDNF in the VTA or throughout the
brain results in more efficacious signaling at the level of the
GABA neurons. This would explain our BDNF effects and would
not contradict the dopamine-specific manipulations undertaken
by Koo et al. (2012) (e.g., the ablation of TrkB in dopaminergic
cells of the VTA resulting in increased morphine place prefer-
ences). Whether VTA dopamine neurons express less TrkB re-
ceptors than the GABA population is unclear, but such a
difference might help explain the discrepancy.
The upregulation of BDNF expression has been associated
with the administration of several drugs of abuse (Kauer and
Malenka, 2007). In particular, it has been observed that BDNF
expression is dramatically increased in the mesolimbic system
during prolonged drug withdrawal (Grimm et al., 2003; Kauer
and Malenka, 2007; Thomas et al., 2008; Vargas-Perez et al.,
2009b) and chronic stress (Berton et al., 2006). Increased levels of
BDNF in the VTA are related to the incubation of cocaine crav-
ing, cue-induced cocaine seeking (Thomas et al., 2008), and the
switch to an opiate-dependent state (Vargas-Perez et al., 2009b).
The present results suggest that BDNF signaling is directly related
to the expression and consolidation of the aversive motivation of
drug withdrawal that lead to a drug-dependent state. The precise
VTA BDNF-related neural adaptations that lead to this outcome
are unclear. High levels of BDNF have been suggested to induce
and sustain early and late long-term potentiation (Minichiello,
2009), regulating both rapid and long-lasting modifications of
circuit activity (Kauer and Malenka, 2007; Minichiello, 2009).
Due to the critical role that BDNF is thought to have in synaptic
plasticity during learning and memory (Kauer and Malenka,
2007;Minichiello, 2009), these findings align with the hypothesis
that processes comparable to associative learning are essential for
the integration and development of drug withdrawal motivation
in the VTA (Berton et al., 2006; Thomas et al., 2008). Our results
are consistent with the conjecture that the withdrawal from ad-
ministration of drugs of abuse elicits an aversive stress response
(Koob and Le Moal, 2005; Kauer and Malenka, 2007; Thomas et
al., 2008; George et al., 2012) that is responsible for the neuronal
plastic changes associated to the development and progression of
drug addiction.
Thus, drug-taking behavior to alleviate a chronic drug-
generated aversive state (e.g., withdrawal) activates adaptive neu-
Figure 4. Motivational effects of withdrawal in opiate-dependent animals after blocking BDNF function in the VTA. a, Knocking down TrkB in the VTAwith LV-siRNAs did not affect spontaneous
opiate somatic withdrawal signs. Both LV-siRNAs (n 8) and LV-GFP (n 8) animals show an increase in percentage abstinence scores over time after 16 h heroin administration with respect to
saline control animals (n 8; *p
 0.05). b, Opiate naive (n 7) and dependent (n 7) LV-siRNAs-treated animals display a reduction in low-frequency (22 kHz) s compared with opiate naive
(n 7) and dependent (n 7) LV-GFP-treated animals (*p
 0.05) during naloxone-precipitated chronic opiate withdrawal during the course of a 10min test session. c, Knocking down TrkB in
theVTAwithLV-siRNAsblocks theplaceaversion for 16hof abstinence frommorphine (3mg/kg) independent rats (n8). In contrast, control opiate-dependentanimals infectedwithLV-GFP (n
8) showconditionedplace aversions (*p
0.05).d, Naloxone-conditioned (5mg/kg)place aversionswereblocked in LV-siRNAs-treated (n8)dependent animals, butnot in LV-GFP-treated (n
8) animals (*p
 0.05). e, Both LV-siRNAs (n 8) and LV-GFP (n 8)-infected animals display a conditioning place aversion to LiCl (5 mg/kg; *p
 0.05). Data represent the means SEM the
absolute times spent in the previously saline and previously drug paired compartments.
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ronal changes (dependent on BDNF) that produce a state of
dependency and, in turn, set up aversive motivational mecha-
nisms in response to drug withdrawal. This negative reinforce-
ment generates a feedforwardmechanism that progressively leads
to an allostatic state involving physiological and behavioral
changes that drive and maintain addiction. Therefore, the ma-
nipulation of VTA TrkB signaling pathway is a promising target
for novel addiction treatments.
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